ischemia–reperfusion injury model #2

Transgenic Diabetes Models

分类：

Model Introduction

Transgenic and genetically engineered diabetes models utilize gene knockout, gene mutation, or transgenic technology to produce specific genetic defects in experimental animals (primarily mice), thereby simulating the pathophysiological processes of human diabetes and its complications (such as diabetic nephropathy, DN). These models offer advantages such as a clear genetic background, short induction time, and stable phenotypic outcomes. Typical models include:

  1. eNOS Knockout Mice: Knocking out the endothelial nitric oxide synthase (eNOS) gene in a db/db mouse background to simulate hypertension and endothelial dysfunction.
  2. OVE26 Mice: A transgenic model on an FVB background capable of spontaneously developing severe diabetic kidney injury.
  3. Ins2 Akita Mice: An Ins2 (C96Y) gene mutation leading to conformational changes in insulin, resulting in β-cell toxicity.
  4. KK-Ay Mice: Established by introducing the Ay gene into KK mice to simulate Type 2 diabetes and its early renal lesions.

Research Applications

These models are primarily used to simulate human Type 1 or Type 2 diabetes and the progression of chronic complications, particularly diabetic nephropathy (DN). Specific applications include:

  1. Pathogenesis Research: Studying the mechanisms of glomerulosclerosis, mesangial matrix expansion, basement membrane thickening, and endothelial dysfunction.
  2. Complication Simulation: Simulating chronic diabetic complications such as hypertension, heart failure, proteinuria, and end-stage renal disease (ESRD).
  3. Fibrosis Research: Monitoring the progression of renal fibrosis through markers such as TGF-β1 and Collagen IV.

Key Points of Experimental Design

  1. Genetic Construction and Background Selection:
    • eNOS Knockout: Gene knockout performed on a db/db mouse background.
    • OVE26: Utilizing an FVB background; can be combined with unilateral nephrectomy to accelerate proteinuria, inflammatory cell infiltration, and the fibrosis process.
    • KK-Ay: Introducing the Ay gene into KK mice to establish obesity and hyperglycemia models.
  2. Observation Period:
    • Ins2 Akita Mice: Observation of hyperglycemia and albuminuria starting from 4 weeks of age.
    • OVE26 Mice: Proteinuria appears at 2 months; nodular glomerulosclerosis is observed at 9 months.
    • eNOS Knockout Mice: Observed up to 26 weeks to evaluate glomerular mesangiolysis and Kimmelstiel-Wilson nodules.
    • KK-Ay Mice: Usually observed up to 20 weeks of age to evaluate segmental glomerulosclerosis.

Key Monitoring Indicators

  1. Biochemical Indicators: Blood glucose levels, HbA1c, 24h proteinuria, urinary protein-to-creatinine ratio (UPCR), glomerular filtration rate (GFR).
  2. Pathological Indicators:
    • Glomerular Changes: Glomerular hypertrophy, mesangial matrix expansion, basement membrane thickening, glomerulosclerosis, Kimmelstiel-Wilson nodules.
    • Vascular and Interstitial Changes: Arteriolar hyalinosis, glomerular mesangiolysis, microaneurysms.
  3. Molecular and Fibrosis Indicators: Expression and localization of TGF-β1, CTGF, Collagen IV, and AGEs (Advanced Glycation End-products).
  4. Other Physiological Indicators: Blood pressure, body weight (e.g., severe obesity in KK-Ay mice).

相关产品